Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma

Silmitasertib (CX-4945) is currently being investigated in clinical trials against various types of cancer. The U.S. Food and Drug Administration (FDA) has already granted orphan drug designation to the compound for the treatment of advanced cholangiocarcinoma, medulloblastoma, and biliary tract can...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Rico, Richter, Anna, Ito, Elisabeth R. D., Murua Escobar, Hugo, Junghanß, Christian, Hinz, Burkhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028559/
https://www.ncbi.nlm.nih.gov/pubmed/35458589
http://dx.doi.org/10.3390/molecules27082394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028559/
https://www.ncbi.nlm.nih.gov/pubmed/35458589
http://dx.doi.org/10.3390/molecules27082394

Ejemplares similares